Citations 22
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina, Marcucci, Guido , Zhao, Weiqiang , Baer, Maria R. , Powell, Bayard L., Westervelt, Peter, DeAngelo, Daniel J. , Sanford, Ben L. , Blum, William , Bloomfield, Clara D. , Stone, Richard M. , Levis, Mark J. , Klepin, Heidi D. , Stock, Wendy , Larson, Richard A. , Uy, Geoffrey , Deangelo, D. J.
Blood Advances | January 25, 2017 | Volume: 1 | Issue: 5 | Pages: 331-340
10.1182/bloodadvances.2016003053
Key Points The addition of sorafenib to chemotherapy for older adults with FLT3-ITD mutated AML is safe and may improve overall survival.
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis
Deol, Abhinav , Sengsayadeth, Salyka, Ahn, Kwang Woo , Wang, Hailin , Aljurf, Mahmoud , Antin, Joseph H. , Cahn, Jean‐Yves , Camitta, Bruce, Chen, Yi‐Bin , Ganguly, Siddhartha , Inamoto, Yoshihiro , Jagasia, Madan , Kamble, Rammurti T., Koreth, John , Litzow, Mark R. , Marks, David I. , Olsson, Richard F. , Rowe, Jacob M. , Saad, Ayman , Sabloff, Mitchell , Schouten, Harry C. , Shea, Thomas C., Soiffer, Robert J. , Uy, Geoffrey L. , Waller, Edmund K. , Wiernik, Peter H. , Wirk, Baldeep , Woolfrey, Ann E. , Bunjes, Donald , Weisdorf, Dan, Khoury, H. Jean , Saber, Wael , Weisdorf, Daniel J. , Battiwalla, Minoo , Bornhäuser, Martin , Camitta, Bruce M., Cutler, Corey S. , Gale, Robert Peter , Hamadani, Mehdi , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Reshef, Ran , Devine, Steven M. , Lima, Marcos de , Sandmaier, Brenda M , Saad, Ayman , Olsson, Richard F , Waller, Edmund K , Weisdorf, Dan , Uy, Geoffrey , Sabloff, Mitchell
Cancer | June 17, 2016 | Volume: 122 | Issue: 19 | Pages: 3005-3014
BACKGROUNDPatients with FMS like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT).METHODSData from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes.RESULTSIn total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild‐type (WT) group (38% [95% confidence interval (CI), 30%‐45%] vs 28% [95% CI, 24%‐33%]; P = .04; relative risk, 1.60 [95% CI, 1.15‐2.22]; P = .0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia‐free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3‐year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%‐57%; WT group: 55%, 95% CI, 50%‐60%; P = .20).CONCLUSIONSThe current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long‐term survivors. Cancer 2016;122:3005‐3014. © 2016 American Cancer Society.